Pharmaceutical And Biologistics Markets By Region 2017 LONDON , GREATER LONDON, UNITED KINGDOM, June 20, 2018 /EINPresswire.com/ -- Pharmaceutical companies are trying to reduce their distribution costs to help compensate for pressures resulting from the increase of low-cost generics, the fall of the blockbuster drug model, and a sharp increase in R&D costs. One result is the growth of the bio-pharmaceutical logistics market, a report from The Business Research Company shows, as the pharma companies outsource their warehousing and transport functions. From a global value of $79.9 billion in 2017 the market is predicted to grow to $96 billion by 2020, at an annual growth rate of 4.7%. Some logistics providers, such as DHL, FedEx Corporation, Panalpina World Transport, and DB Schenker, have developed a special capability for the physical distribution of drugs. These businesses can cut costs by combining loads from a range of manufacturers, and by deploying technological solutions … [Read more...] about Challenges To Big Pharma Are Helping Drive The Bio-Pharmaceutical Logistics Market
COVINGTON, Ky. (Jun 19, 2018) – Sometimes things come full circle. Fourteen years ago, CancerFree KIDS awarded its very first research grant to a young investigator at Cincinnati Children’s Hospital Medical Center (CCHMC) to study a long shot idea that no one else would fund. This year CancerFree KIDS announced it will fund the first pediatric clinical trial for the drug that resulted from that long shot. Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain tumors, announced today a $50,000 grant awarded by CancerFree KIDS to Nationwide Children’s Hospital in Columbus, Oh. The monies will be used to initiate a Phase I Pediatric Trial in Solid and Rare Tumors using Bexion’s first in class drug, BXQ-350. The precursor of the clinical formulation of BXQ-350, called SapC-DOPS, was an accidental discovery at CCHMC by a rare disease researcher, Dr. Xiaoyang Qi. Bexion was founded in 2006 when the Company licensed this … [Read more...] about Bexion Pharmaceuticals announces grant from CancerFree KIDS
/EIN News/ -- NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microchip Technology Incorporated (NASDAQ:MCHP), New Jersey Resources Corporation (NYSE:NJR), Brown-Forman Corporation (NYSE:BF-B), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), Team, Inc. (NYSE:TISI), and Solaris Oilfield Infrastructure, Inc. (NYSE:SOI), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. Complimentary Access: Research Reports Full copies of recently published reports are available to readers at the links below. MCHP DOWNLOAD: http://Fundamental-Markets.com/register/?so=MCHP http://Fundamental-Markets.com/register/?so=NJR http://Fundamental-Markets.com/register/?so=BF-B http://Fundamental-Markets.com/register/?so=PCRX http://Fundamental-Markets.com/register/?so=TISI … [Read more...] about Consolidated Research: 2018 Summary Expectations for Microchip Technology, New Jersey Resources, Brown-Forman, Pacira Pharmaceuticals, Team, and Solaris Oilfield Infrastructure — Fundamental Analysis, Key Performance Indications
-- Further Improvements Observed in Bardet-Biedl Syndrome Patients; Initial Proof-of-Concept Data in Alström Syndrome Demonstrates Significant Weight Loss and Decreased Hunger ---- Rhythm Plans to Initiate Combined Pivotal Phase 3 Trial in Bardet-Biedl Syndrome and Alström Syndrome in 2018 ---- Preliminary Data in Patients with POMC and Other MC4 Pathway Heterozygous Deficiency Obesities and POMC Epigenetic Disorders Demonstrate Clinically-Meaningful Reductions in Weight and Hunger -- BOSTON, June 18, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced new topline clinical data from its ongoing Phase 2 basket studies of setmelanotide, a first-in-class melanocortin-4 receptor (MC4R) agonist, including updated data in patients with Bardet-Biedl Syndrome (BBS), initial proof-of-concept data in … [Read more...] about Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity
/EIN News/ -- NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Outfront Media Inc. (NYSE:OUT), Enel Chile S.A. (NYSE:ENIC), Banc of California, Inc. (NYSE:BANC), Northern Dynasty Minerals, Ltd. (NYSE:NAK), Collegium Pharmaceutical, Inc. (NASDAQ:COLL), and Petroleo Brasileiro S.A.- Petrobras (NYSE:PBR-A), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. Complimentary Access: Research Reports Full copies of recently published reports are available to readers at the links below. OUT DOWNLOAD: http://Fundamental-Markets.com/register/?so=OUT http://Fundamental-Markets.com/register/?so=ENIC http://Fundamental-Markets.com/register/?so=BANC http://Fundamental-Markets.com/register/?so=NAK http://Fundamental-Markets.com/register/?so=COLL … [Read more...] about New Research: Key Drivers of Growth for Outfront Media, Enel Chile, Banc of California, Northern Dynasty Minerals, Collegium Pharmaceutical, and Petroleo Brasileiro S.A.